Friday, 21 October 2011
AstraZeneca today announced it will present key results from health economics sub-studies from the PLATO trial at the upcoming International Society for Pharmacoeconomics and Outcomes Research (ISPOR) EU meeting, 5-8 November in Madrid. Data from eight countries will show that using BRILIQUE (ticagrelor) plus aspirin to treat acute coronary syndrome (ACS) patients for one year is associated with cost-savings, gain in quality-adjusted life years, and life-years gained compared to treatment with both generic and branded clopidogrel plus aspirin. In the EU, BRILIQUE is indicated for the prevention of atherothrombotic events in adult patients with ACS.
The PLATO health economics sub-studies used local cost data and clinical data from Brazil, Canada, Germany, Greece, Holland, Mexico, Poland, and Spain to evaluate the clinical effect observed in PLATO, as well as cost considerations for treating ACS patients with BRILIQUE versus generic and branded clopidogrel. Across each country and measurement, results showed that even at a higher price, BRILIQUE is a cost-effective treatment for ACS patients compared to generic and/or branded clopidogrel.
“It’s critical that we deliver solutions that demonstrate how our medications improve quality-of-life and reduce mortality, as well as alleviate the cost burden on the global healthcare system caused by hospital readmissions and expensive procedures,” said Tony Zook, Executive Vice President of AstraZeneca’s Global Commercial Organisation. “AstraZeneca works closely with our stakeholders, starting early in the drug development process, to effectively address their questions about the value of our medicines, in order to ensure patients will ultimately benefit from cost-effective therapeutic options.”
Data for one additional AstraZeneca brand, CRESTOR (rosuvastatin) is now available in ISPOR’s Value in Health publication, and will also be presented at the group’s annual European meeting next month, along with the BRILIQUE health economics sub-studies:
- BRILIQUE health economics sub-studies for Brazil (abstract #33322), Canada (abstract #33335), Germany (abstract #32529), Greece (abstract #34099), Holland (abstract #32584), Mexico (abstract #33517), Poland (abstract #33653), and Spain (abstract #33160), will be presented Monday 7 November, 8:00-19:30
- The Archimedes model demonstrated that CRESTOR (rosuvastatin) a cholesterol-lowering medication, reduced the risk of major adverse cardiac events (MACE), as compared to atorvastatin in higher-risk patients (abstract #33997) will be presented Monday 7 November, 8:00-19:30
NOTES TO EDITORS
BRILIQUE is an oral antiplatelet treatment for ACS. BRILIQUE is a direct-acting P2Y12 receptor antagonist in a new chemical class called cyclopentyltriazolopyrimidines (CPTPs). BRILIQUE is the first reversibly-binding oral ADP receptor antagonist to be approved for use in ACS.
In the European Union, BRILIQUE, a prescription oral antiplatelet treatment, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with ACS (unstable angina, NSTEMI, or STEMI), including patients managed medically and those who are managed with percutaneous coronary intervention (PCI) or Coronary Artery Bypass Grafting (CABG). The PLATO trial (A Study of PLATelet Inhibition and Patient Outcomes) was the pivotal phase III study that formed the basis of the EU label.
BRILIQUE is currently reimbursed in nine countries. The product is approved in 47 countries, including in the European Union under the trade name BRILIQUE and in the US, Brazil, Canada, and Australia, under the trade name BRILINTA.
BRILIQUE and BRILINTA are trademarks of the AstraZeneca group of companies.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
Esra Erkal-Paler +44 20 7604 8030 (24 hours)
Abigail Baron +44 20 7604 8034 (24 hours)
Isabelle Jouin +44 20 7604 8031 (24 hours)
Investor Enquiries UK
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043